Anthony Chamberlain
Overview
Explore the profile of Anthony Chamberlain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
150
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dias A, Brook M, Bancroft E, Page E, Chamberlain A, Saya S, et al.
BJUI Compass
. 2023 Apr;
4(3):361-373.
PMID: 37025481
Objectives: The relation of serum androgens and the development of prostate cancer (PCa) is subject of debate. Lower total testosterone (TT) levels have been associated with increased PCa detection and...
2.
Benafif S, Ni Raghallaigh H, McGrowder E, Saunders E, Brook M, Saya S, et al.
BJU Int
. 2021 Jul;
129(3):325-336.
PMID: 34214236
Objectives: To assess the feasibility and uptake of a community-based prostate cancer (PCa) screening programme selecting men according to their genetic risk of PCa. To assess the uptake of PCa...
3.
Bancroft E, Saya S, Brown E, Thomas S, Taylor N, Rothwell J, et al.
J Med Genet
. 2019 Nov;
57(4):226-236.
PMID: 31719169
Background: Germline gene pathogenic variants (pv) cause a very high lifetime risk of developing cancer, almost 100% for women and 75% for men. In the UK, annual MRI breast screening...
4.
Page E, Bancroft E, Brook M, Assel M, Hassan Al Battat M, Thomas S, et al.
Eur Urol
. 2019 Sep;
76(6):831-842.
PMID: 31537406
Background: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2...
5.
Bancroft E, Saya S, Page E, Myhill K, Thomas S, Pope J, et al.
BJU Int
. 2018 May;
123(2):284-292.
PMID: 29802810
Objectives: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with...
6.
Mikropoulos C, Hutten Selkirk C, Saya S, Bancroft E, Vertosick E, Dadaev T, et al.
Br J Cancer
. 2018 Mar;
118(6):e17.
PMID: 29509747
This corrects the article DOI: 10.1038/bjc.2017.429.
7.
Mikropoulos C, Hutten Selkirk C, Saya S, Bancroft E, Vertosick E, Dadaev T, et al.
Br J Cancer
. 2018 Jan;
118(2):266-276.
PMID: 29301143
Background: Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a...
8.
Saya S, Killick E, Thomas S, Taylor N, Bancroft E, Rothwell J, et al.
Fam Cancer
. 2017 Jan;
16(3):433-440.
PMID: 28091804
In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study...